John Oyler sold $25M of ONC
Chief Executive Officer at BeOne Medicines Ltd.. 101,000 shares at an average of $244.30, traded Mar 3, 2025, filed Mar 5, 2025.
Score components
- +25RoleCEO
- +25Trade size$24.7M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001651308-25-000039, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 3, 2025 | MOption exercise Ordinary Shares | +1,220,531 | $0.50 | $610k | 4,199,364 | Mar 5, 2025 |
| Mar 3, 2025 | MOption exercise American Depositary Shares | +101,000 | $6.50 | $657k | 101,000 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale American Depositary Shares | -5,956 | $240.53 | $1.4M | 95,044 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale American Depositary Shares | -13,816 | $241.38 | $3.3M | 81,228 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale American Depositary Shares | -8,192 | $242.46 | $2.0M | 73,036 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale American Depositary Shares | -11,195 | $243.44 | $2.7M | 61,841 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale American Depositary Shares | -4,910 | $244.45 | $1.2M | 56,931 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale American Depositary Shares | -18,386 | $244.56 | $4.5M | 38,545 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale American Depositary Shares | -1,090 | $245.36 | $267k | 37,455 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale American Depositary Shares | -19,232 | $245.51 | $4.7M | 18,223 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale American Depositary Shares | -7,243 | $246.57 | $1.8M | 10,980 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale American Depositary Shares | -6,480 | $247.63 | $1.6M | 4,500 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale American Depositary Shares | -3,900 | $248.63 | $970k | 600 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale American Depositary Shares | -600 | $249.25 | $150k | 0 | Mar 5, 2025 |
| Mar 3, 2025 | MOption exercise Share Option (Right to Buy)derivative | -2,533,531 | $0.00 | $0 | 7,566,969 | Mar 5, 2025 |
Related signals
Other insiders at BeOne Medicines Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 39Weak | BeOne Medicines Ltd. | Chan Henry Lee SVP, General Counsel | $418k 1,115 shares | -100% | |
| 33Weak | BeOne Medicines Ltd. | Xiaodong Wang director, other | $11M 31,028 shares | -100% | |
| 33Weak | BeOne Medicines Ltd. | Xiaodong Wang director, other | $13M 38,287 shares | -527% | |
| 49Moderate | BeOne Medicines Ltd. | Titus B. Ball Principal Accounting Officer | $47k 132 shares | -100% | |
| 65Notable | BeOne Medicines Ltd. | John Oyler Chief Executive Officer | $9.1M 27,803 shares | -100% | |
| 40Moderate | BeOne Medicines Ltd. | Chan Henry Lee SVP, General Counsel | $3.3M 10,006 shares | -900% | |
| 55Moderate | BeOne Medicines Ltd. | Lai Wang Global Head of R&D | $1.8M 5,000 shares | -100% | |
| 69Notable | BeOne Medicines Ltd. | Corazon (Corsee) D. Sanders director | $898k 2,665 shares | -100% | |
| 56Moderate | BeOne Medicines Ltd. | Titus B. Ball Principal Accounting Officer | $40k 122 shares | -100% | |
| 40Moderate | BeOne Medicines Ltd. | Chan Henry Lee SVP, General Counsel | $3.3M 11,013 shares | -990% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.